60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it will disclose the outcome of the interim analysis from its clinical study evaluating tafenoquine in patients hospitalized with severe babesiosis (NCT06207370) on October 6, 2026.